Wrap Technologies, Inc. (NASDAQ: WRAP), a provider of non-lethal response technologies and public safety solutions, has appointed former New York City Police Department Deputy Commissioner Edward Delatorre Jr. to its Board of Directors, effective October 20, 2026. The appointment carries significance beyond a routine board addition: Delatorre is the official who helped introduce Narcan into NYPD patrol operations, guiding the program from a Staten Island pilot to citywide adoption and later sharing the model with departments nationally and internationally.
For WRAP, the parallel is direct. The company frames its own mission as making Non-Lethal Response(TM) technology, training and policy a practical, repeatable capability that agencies can adopt and sustain. Delatorre's experience building a program around a single intervention, rather than simply distributing a tool, is precisely the kind of operational know-how that can determine whether a new technology becomes routine practice or remains a pilot project. His work on Narcan demonstrated that adoption at scale depends on training, policy and logistics as much as on the product itself.
The timing matters. Law enforcement agencies face growing pressure to adopt alternatives that reduce the risk of lethal force, but many struggle to move from initial interest to sustained deployment. Delatorre's record offers a template for that transition. As Wrap Technologies, Inc. (NASDAQ: WRAP) has appointed him to its board, the company is effectively adding a board member who has already solved the adoption problem once, in one of the largest police departments in the country.
The announcement also signals how WRAP intends to position itself in the public safety market. By bringing in a leader known for scaling a health intervention across a major agency, the company is emphasizing implementation and policy alongside hardware. That emphasis could matter to agency leaders who need to justify procurement decisions to city officials and communities. The full details of the appointment were first reported through Read More coverage distributed by www.newmediawire.com.
Investors and industry observers will watch whether Delatorre's board role translates into faster, more structured adoption of WRAP's offerings. The company's forward-looking statements acknowledge that product adoption, strategy and the contributions of its board are subject to risks and uncertainties, and actual results may differ materially. Still, the appointment makes a clear argument: the next phase of non-lethal response may be less about invention and more about the unglamorous work of making programs stick. For a company trying to move its technology from niche to standard practice, that is the central challenge, and it now has a board member who has met it before.
